Between 2017 and 2019, Liz Dark and our asthma team, led by Professor Tim Harrison of the NIHR Nottingham BRC, recruited severe asthma patients into the phase 3b #ANDHI study treating patients with #Benralizumab.
ANDHI was done to assess the efficacy of #benralizumab, including onset of effect and impact on health-related quality of life (HRQOL), exacerbation rate, lung function, and nasal polyposis symptoms.
The latest results have recently been published in the #Lancet, "Onset of effect and impact on health-related quality of life, exacerbation rate, lung function, and nasal polyposis symptoms for patients with severe eosinophilic asthma treated with benralizumab (ANDHI): a randomised, controlled, phase 3b trial"; https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(20)30414-8/fulltext
Interpretation
the results extend the efficacy profile of #benralizumab for patients with severe eosinophilic asthma, showing early clinical benefits in patient-reported outcomes, HRQOL, lung function, and nasal polyposis symptoms.
